The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

Volume: 12, Issue: 3, Pages: 670 - 670
Published: Mar 13, 2020
Abstract
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. Despite its efficacy, primary or acquired resistance frequently develops, particularly in advanced stages of the disease. Second generation ADCs targeting HER2 are meant...
Paper Details
Title
The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1
Published Date
Mar 13, 2020
Journal
Volume
12
Issue
3
Pages
670 - 670
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.